| P2093 | author name string | Ian N Hines | |
| | Michael Kremer | |
| | Doris Henne-Bruns | |
| | Giulia Manzini | |
| | Fabius Hapke | |
| P2860 | cites work | Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer | Q24193871 |
| | Postoperative adjuvant chemotherapy in rectal cancer operated for cure | Q24201072 |
| | Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial | Q29396936 |
| | Effective surgical adjuvant therapy for high-risk rectal carcinoma | Q33387384 |
| | Minimization, by its nature, precludes allocation concealment, and invites selection bias | Q34091576 |
| | The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. | Q34220182 |
| | Statistics notes: Concealing treatment allocation in randomised trials | Q34345415 |
| | Chemotherapy with preoperative radiotherapy in rectal cancer | Q34570877 |
| | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. | Q34725978 |
| | Chemoradiotherapy and adjuvant chemotherapy for rectal cancer | Q37353934 |
| | Validity and power considerations on hypothesis testing under minimization | Q40442495 |
| | The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin | Q41499548 |
| | Chemoradiotherapy for rectal cancer--when, why, and how? | Q45117142 |
| | Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials | Q45197627 |
| | Meta-analysis as evidence: building a better pyramid. | Q52874622 |
| | Minimization: A new method of assigning patients to treatment and control groups | Q52909206 |
| | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 |
| | Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan | Q71833709 |
| | Adjuvant Chemotherapy in Cancer of the Colon and Rectum: Demonstration of Effectiveness of Prolonged 5-FU Chemotherapy in a Prospectively Controlled, Randomized Trial | Q72653039 |
| | Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates | Q76380737 |
| | Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC) | Q84275106 |
| | Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424073 |
| | State of the Art - Rectal Cancer Surgery | Q90644219 |
| | Validity of studies suggesting preoperative chemotherapy for resectable thoracic esophageal cancer: A critical appraisal of randomized trials | Q92841220 |
| P433 | issue | 4 | |
| P304 | page(s) | 503-513 | |
| P577 | publication date | 2020-04-01 | |
| P1433 | published in | World journal of gastrointestinal oncology | Q27723329 |
| P1476 | title | Adjuvant chemotherapy in curatively resected rectal cancer: How valid are the data? | |
| P478 | volume | 12 | |